Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-11-02

Clinical Trial Update: EpiCeram for Skin Protection in Healthcare Workers [NA]

View source ↗

Summary

A terminated clinical trial evaluated EpiCeram for protection against irritant contact dermatitis in healthcare workers; results were posted in November 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EpiCeram

Snippet

Sponsor: Primus Pharmaceuticals | Conditions: Irritant Contact Dermatitis | NA | Status: TERMINATED | Results posted: 2022-11-02